{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:30:56Z","timestamp":1787812256371,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40271-026-00813-6","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:29:24Z","timestamp":1776356964000},"page":"699-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct03812224","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-8825","authenticated-orcid":false,"given":"Carla","family":"Dias-Barbosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaka","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Duenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Hareendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nagamitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Tatsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"1","key":"813_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15\u201322.","journal-title":"Cephalalgia"},{"issue":"1","key":"813_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8\u201319.","journal-title":"Headache"},{"issue":"1","key":"813_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111.","journal-title":"J Headache Pain"},{"issue":"11","key":"813_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, et al. Comprehensive population-based survey of migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945\u201355.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"813_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205\u201322.","journal-title":"Neurol Ther."},{"issue":"11","key":"813_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T. Social burden of people with the migraine diagnosis in Japan: Evidence from a population-based cross-sectional survey. BMJ Open. 2020;10(11):e038987.","journal-title":"BMJ Open"},{"issue":"1","key":"813_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110.","journal-title":"J Headache Pain"},{"issue":"1","key":"813_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.","journal-title":"J Headache Pain"},{"issue":"1","key":"813_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12955-016-0542-3","volume":"14","author":"S Mannix","year":"2016","unstructured":"Mannix S, Skalicky A, Buse DC, Desai P, Sapra S, Ortmeier B, et al. Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health Qual Life Outcomes. 2016;14(1):143.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"813_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/head.14151","volume":"61","author":"PM Estave","year":"2021","unstructured":"Estave PM, Beeghly S, Anderson R, Margol C, Shakir M, George G, et al. Learning the full impact of migraine through patient voices: A qualitative study. Headache. 2021;61(7):1004\u201320.","journal-title":"Headache"},{"issue":"12","key":"813_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518\u201334.","journal-title":"Cephalalgia"},{"issue":"9656","key":"813_CR12","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115\u201323.","journal-title":"Lancet"},{"issue":"16","key":"813_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304\u201312.","journal-title":"Neurology"},{"key":"813_CR14","unstructured":"Amgen, Inc. Aimovig (erenumab-aooe). Full prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s011lbl.pdf. Accessed 12 Jan 2024."},{"key":"813_CR15","unstructured":"Novartis Europharm Limited. Aimovig (erenumab). Summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 12 Jan 2024."},{"issue":"6","key":"813_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61(6):927\u201335.","journal-title":"Headache"},{"issue":"1","key":"813_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01313-8","volume":"22","author":"K Hirata","year":"2021","unstructured":"Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R, et al. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22(1):110.","journal-title":"J Headache Pain"},{"issue":"8","key":"813_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068616","volume":"13","author":"K Hirata","year":"2023","unstructured":"Hirata K, Takeshima T, Sakai F, Numachi Y, Yoshida R, Koukakis R, et al. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open. 2023;13(8):e068616.","journal-title":"BMJ Open"},{"issue":"10","key":"813_CR19","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/head.14013","volume":"60","author":"JH Ford","year":"2020","unstructured":"Ford JH, Kurth T, Starling AJ, Ayer DW, Wietecha LA, Port MD, et al. Migraine headache day response rates and the implications to patient functioning: an evaluation of 3 randomized phase 3 clinical trials of galcanezumab in patients with migraine. Headache. 2020;60(10):2304\u201319.","journal-title":"Headache"},{"key":"813_CR20","unstructured":"U.S. Food & Drug Administration. Patient-focused drug development: methods to identify what is important to patients. guidance for industry, food and drug administration staff, and other stakeholders. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 26 Feb 2026."},{"key":"813_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-025-00795-x","author":"C Dias-Barbosa","year":"2026","unstructured":"Dias-Barbosa C, Kimel M, Rolska-Wojcik P, Bailey K, Eseyin OR, Martin ML. Beyond numbers: uses and value of in-trial interview data for regulatory and health technology assessment (HTA) decision making. Patient. 2026. https:\/\/doi.org\/10.1007\/s40271-025-00795-x.","journal-title":"Patient"},{"issue":"3","key":"813_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae422","volume":"18","author":"Y Meuleman","year":"2025","unstructured":"Meuleman Y, Schade van Westrum E, Bos WJW, Mooijaart SP, van Buren M, Tripepi G, et al. Designing qualitative research with value in the clinical and epidemiological context: what, why and how. Clin Kidney J. 2025;18(3):sfae422.","journal-title":"Clin Kidney J"},{"issue":"3","key":"813_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40271-024-00726-2","volume":"18","author":"N Williamson","year":"2025","unstructured":"Williamson N, Howse C, Hodson N, Stein J, Arbuckle R. Qualitative in-trial interviews: methods, challenges, and best practice. Patient. 2025;18(3):199\u2013209.","journal-title":"Patient"},{"key":"813_CR24","unstructured":"Hasebe M, Takashima T, Igarashi H, Duenas A, Dias-Barbosa C, Chandler D, et al. Japanese clinical trial participants' experiences of migraine and erenumab treatment. Paper presented at the 62nd Annual Meeting of the Japanese Society of Neurology, Kyoto, Japan, 19-22 May 2021. 2021."},{"key":"813_CR25","volume-title":"ATLAS.ti 8 Windows user manual","author":"S Friese","year":"2019","unstructured":"Friese S, Ringmayr TG. ATLAS.ti 8 Windows user manual. Berlin: ATLAS.ti Scientific Software Development GmbH; 2019."},{"key":"813_CR26","unstructured":"Friese S, Soratto J, Pires D. Carrying out a computer-aided thematic content analysis with ATLAS.ti. MMG Working Papers. 2018;18-02."},{"issue":"12","key":"813_CR27","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1111\/ene.15037","volume":"28","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Constantin L, Ebel-Bitoun C, Igracki Turudic I, Hitier S, Amand-Bourdon C, et al. Multinational descriptive analysis of the real-world burden of headache using the Migraine Buddy application. Eur J Neurol. 2021;28(12):4184\u201393.","journal-title":"Eur J Neurol"},{"issue":"10","key":"813_CR28","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1177\/0333102418789072","volume":"38","author":"DC Buse","year":"2018","unstructured":"Buse DC, Lipton RB, Hallstr\u00f6m Y, Reuter U, Tepper SJ, Zhang F, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38(10):1622\u201331.","journal-title":"Cephalalgia"},{"issue":"5","key":"813_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/jnnp-2020-324396","volume":"92","author":"M Lanteri-Minet","year":"2021","unstructured":"Lanteri-Minet M, Goadsby PJ, Reuter U, Wen S, Hours-Zesiger P, Ferrari MD, et al. Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: Results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2021;92(5):466\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"813_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache S. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341.","journal-title":"Headache"},{"issue":"1","key":"813_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40120-021-00236-5","volume":"10","author":"Y Tatsuoka","year":"2021","unstructured":"Tatsuoka Y, Takeshima T, Ozeki A, Matsumura T. Treatment satisfaction of galcanezumab in Japanese patients with episodic migraine: a phase 2 randomized controlled study. Neurol Ther. 2021;10(1):265\u201378.","journal-title":"Neurol Ther"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00813-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:33Z","timestamp":1787664393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00813-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00813-6","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.D.-B., A.D., and A.H. contributed to conception and design of the study; analysis and interpretation of data for the manuscript; and drafting the manuscript. H.I., S.K., S.T., N.S., H.D., T.N., Y.T., Y.M., M.H., and T.T. contributed to acquisition and interpretation of data for the manuscript. All authors contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript.","order":1,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.D.-B. and A.D. are employees of PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, which was paid by Amgen to conduct the study and develop the manuscript. H.I. has received payments\/honoraria for lectures\/presentations\/speaker bureaus\/manuscript writing\/educational events from Amgen, Daiichi Sankyo, Eisai, Eli Lilly, Otsuka Pharmaceutical, Pfizer, Sawai Pharmaceutical, and Sumitomo Pharma. A.H. is a former employee of PPD Evidera Patient-Centered Research, Thermo Fisher Scientific. S.K., N.S., and Y.M. have received honoraria for lectures from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka Pharmaceutical. S.T., H.D., T.N., and Y.T. have nothing to declare. M.H. is an employee of, and owns stock in, Amgen, which funded the study. T.T. has received consulting fees from Hedgehog MedTech, Sawai Pharmaceutical, and Teijin Pharma, and honoraria for lectures from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka Pharmaceutical.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol, including the qualitative interview substudy, was approved by the ethics committee (EC) or institutional review board (IRB) at each study site. Names of sites that recruited participants to the qualitative interview study and details of the corresponding ECs\/IRBs are given in Table\n                      \n                      in the ESM. Please note that ECs and IRBs in Japan do not provide approval numbers. Informed consent was obtained from all trial participants. Additional informed consent was obtained from participants in the qualitative interview substudy prior to their participation.","order":3,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qualified researchers may request study data from Amgen clinical studies. Further details are available from:\n                      \n                      .","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}